Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 14:18:411-424.
doi: 10.2147/PPA.S436540. eCollection 2024.

Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes

David Kerr  1 , Jigar Ramesh Rajpura  2 , Tarlan Namvar  3
Affiliations

Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes

David Kerr et al. Patient Prefer Adherence. .

Abstract

Purpose: The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options.

Patients and methods: In a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naïve and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors.

Results: Most respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users ("insulin experienced") reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin.

Conclusion: Discussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations.

Keywords: diabetes mellitus; insulin; long-acting; patient preference; provider preference; surveys and questionnaires; type 2.

PubMed Disclaimer

Conflict of interest statement

DK is an employee of Sutter Health, has received consultancy fees from Sanofi, Abbott Rapid Diagnostics, Proteomics and Better Therapeutics and research support from Novo Nordisk and Abbott Diabetes Care. JRR is an employee of and shareholder in Novo Nordisk Inc. At the time of the study, TN was an employee of Novo Nordisk Inc. The authors report no other conflicts of interest in this work.

Figures

None
Graphical abstract
Figure 1
Figure 1
Agreement with Once-Weekly Insulin Attributes for Management of T2D Among Patients who are Insulin Naïve and Insulin Experienced.
Figure 2
Figure 2
Healthcare Providers’ Level of Agreement with Once-Weekly Insulin Attributes for Management of type 2 diabetes.
Figure 3
Figure 3
Basal Insulin Preference among Patients in the Base Case Scenario.
Figure 4
Figure 4
Basal Insulin Preference among HCPs in the Base Case Scenario (when asked to indicate the proportion of patients eligible for basal insulin for whom they would recommend or prescribe a once-weekly option as part of the DCE).
Figure 5
Figure 5
Likelihood of Patients with Type 2 Diabetes to Ask their Healthcare Provider About Once-Weekly Basal Insulin.
None
See this image and copyright information in PMC

References

    1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107–111. doi:10.2991/jegh.k.191028.001 - DOI - PMC - PubMed
    1. National Diabetes Statistics Report website; 2002. Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed September 21, 2023.
    1. Fang M, Wang D, Coresh J, Selvin E. Undiagnosed Diabetes in U.S. Adults: prevalence and Trends. Diabetes Care. 2022;45(9):1994–2002. doi:10.2337/dc22-0242 - DOI - PMC - PubMed
    1. Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416–426. doi:10.2337/dc17-1144 - DOI - PMC - PubMed
    1. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–s157. doi:10.2337/dc23-S009 - DOI - PMC - PubMed